Viatris

Viatris in Fortune Rankings

Viatris is a global pharmaceutical company with over 250 medicines on the World Health Organization’s List of Essential Medicines, which treat a range of conditions including cardiovascular, immunological, cancer, infectious diseases, and diabetes. Viatris products include generics and branded drugs such as Xanax, Lyrica, and Viagra. Viatris supplies medicines to 1 billion people around the world each year. The company also has a number of partnerships, including with the European Innovation Partnership on Active and Healthy Ageing, to improve prevention and treatment of noncommunicable diseases. The company was born from the merger of Mylan and Upjohn in 2020.

World’s 25 Best Workplaces 2025

Viatris ranks No. 19 on the 2025 World’s 25 Best Workplaces list.

Read the Great Place To Work Review

Courtesy of Viatris

Updated:6/3/26
Country/Territory:U.S.
Headquarters:Canonsburg, Pa.
Industry:Pharmaceuticals
CEO:Scott A. Smith
Website:https://www.viatris.com

Ticker:VTRS
Company type:Public
Revenues ($M):$14,300
Profits ($M):$-3,515
Market value ($M):$15,555
Number of employees:30,000

Market value as of March 31, 2026.

Impact Segment:Public Health/Nutrition
Sector:Health Care

Sector:Health Care
CEO/Top executive:Scott A. Smith
Group headquarters:U.S.
HQ location:U.S.
GPTW national list:Austria, Belgium, Bulgaria, Croatia, Czech Republic, Denmark, Estonia, Hungary, Latvia, Lithuania, Netherlands, Norway, Portugal, Romania, Slovenia, Spain, Sweden, Switzerland, Turkey
Woman CEO:no
Number of Years on List:1

World's Best list history:New
Countries where the company was recognized on a GPTW national list:Albania, Australia, Austria, Belgium, Bosnia and Herzegovina, Brazil, Bulgaria, Canada, Costa Rica, Croatia, Czechia, Denmark, Egypt, Estonia, Finland, France, Germany, Greater China, Greece, Hungary, India, Italy, Kuwait, Latvia, Lithuania, Malaysia, Mexico, Morocco, The Netherlands, New Zealand, Nigeria, Norway, Panama, Philippines, Poland, Portugal, Puerto Rico, Qatar, Romania, Saudi Arabia, Serbia, Singapore, Slovakia, Slovenia, Spain, Sweden, Switzerland, Thailand, Turkey, UAE, United Kingdom, United States, Vietnam, Zambia

$ millions% change
Revenues ($M):$14,299.9-3%
Profits ($M):$-3,514.9-
Assets ($M):$37,193.1-
Total Stockholder Equity ($M):$14,711.3-

Profit as % of Revenues:-24.6%
Profits as % of Assets:-9.5%
Profits as % of Stockholder Equity:-23.9%

Earnings Per Share ($):-3.00
EPS % Change (from prior fiscal year):-
EPS % Change (5 year annual rate):-
EPS % Change (10 year annual rate):-

Total Return to Investors (last year):5%
Total Return to Investors (5 year, annualized):-3.9%
Total Return to Investors (10 year, annualized):-

Viatris stock chart

Viatris in Fortune Rankings

View the Full List